Delving into the Latest Updates on BMS-986458 with Synapse

Overview

Basic Info

Drug Type

Molecular glue

Synonyms

Target

BCL6

Action

inhibitors

Mechanism

BCL6 inhibitors(B-cell lymphoma 6 protein inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases

Active Indication

Non-Hodgkin's lymphoma refractory

Inactive Indication-

Originator Organization

Bristol Myers Squibb Co.

Active Organization

Bristol Myers Squibb Co.

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader (LDD) of BCL6 (BCL6 LDD), as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin Lymphoma.

Start Date29 Dec 2023

Sponsor / Collaborator

Bristol Myers Squibb Co.

100 Clinical Results associated with BMS-986458

Login to view more data

100 Translational Medicine associated with BMS-986458

Login to view more data

100 Patents (Medical) associated with BMS-986458

Login to view more data

100 Deals associated with BMS-986458

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Hodgkin's lymphoma refractory	Phase 2	Spain	Bristol Myers Squibb Co.	29 Dec 2023
Non-Hodgkin's lymphoma refractory	Phase 2	Germany	Bristol Myers Squibb Co.	29 Dec 2023
Non-Hodgkin's lymphoma refractory	Phase 2	France	Bristol Myers Squibb Co.	29 Dec 2023
Non-Hodgkin's lymphoma refractory	Phase 2	Netherlands	Bristol Myers Squibb Co.	29 Dec 2023
Non-Hodgkin's lymphoma refractory	Phase 2	United States	Bristol Myers Squibb Co.	29 Dec 2023
Non-Hodgkin's lymphoma refractory	Phase 2	Switzerland	Bristol Myers Squibb Co.	29 Dec 2023